We identify and target disrupted cross-organ pathways effectively with innovative, food-, repurposed drug-based and technological solutions to reduce the burden of multi-morbidity and consequent ill-health.

We believe a multidisciplinary team science approach is essential to identify shared disease mechanisms and modifiable drivers of multi-morbidity in gastro-intestinal and liver disorders, and patient and community involvement are integral to our work.

Our leading experimental medicine and early translations studies involve GI physiology, liver metabolism, molecular microbiology, gut microbial interactions, the genomics of complex and monogenic diseases. In collaboration with the pioneering Sir Peter Mansfield Imaging Centre we will investigate multi-organ interactions across the life span. We aim to develop innovative solutions to tackle the escalating problem of chronic disease clusters by harnessing expertise in food sciences, bioengineering and our extensive collaboration with industry.

We have five research areas:

• Inter-organ pathways
• Multi-organ disorders
• Future food
• Next generation therapeutics
• Innovative technologies in translation

We have experience with knowledge transfer mechanisms (patents, CE marking, licensing) and development pathway (DPFS, NIHR EME, i4i, Innovate UK, IMI) funding schemes.